Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from "neutral," saying that the pharma play has high visibility and revenue predictability. Cowen also assumes an expanded EU label for Revlimid in 2015 despite last week's regulatory setback for the drug. Cowen's note comes after other firms cut their price targets on Celgene.